Ursula A. Matulonis, MD, on Various Advancements in Gynecologic Cancers Presented at SGO 2021

Video

CancerNetwork® discussed updates in the treatment of gynecologic cancers with Ursula A. Matulonis, MD.

CancerNetwork® sat down with Ursula A. Matulonis, MD, who is chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute as well as a professor of medicine at Harvard Medical School, to discuss data presented at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer and what abstracts she believes have the greatest potential to shift the treatment paradigm in various gynecologic cancers.

She first pointed to data presented from the KEYNOTE-775 trial (NCT03517449), which showed that pembrolizumab (Keytruda) plus lenvatinib (Lenvima) administered to patients with advanced, metastatic, or recurrent endometrial cancer who had previously received 1 prior platinum-based regimen in any setting resulted in improved progression-free survival (PFS) and overall survival (OS) versus those treated with physician’s choice therapy.

She also mentioned updated results of the phase 2 KEYNOTE-158 study (NCT02628067) of pembrolizumab in the treatment of advanced cervical cancer as well as a study examining tumor infiltrating lymphocytes, or TILS (LN-145), in recurrent cervical cancer.1,2

Transcription:

They are a lot of practice-changing abstracts being presented. Obviously, KEYNOTE-775 was presented showing improvement of pembrolizumab with lenvatinib in women with recurrent endometrial cancer, mostly in mismatch-repair proficient tumors. That’s practice changing. I gave up a distillation of that on Friday and it really opens up the next steps for improvement in outcomes for women with endometrial cancer and puts a spotlight on this cancer that it’s never [had] before. That’s really exciting for me to see.

There was also data on pembrolizumab presented yesterday, [updating] results in recurrent cervix cancer. Then [the was an abstract about] tumor infiltrating lymphocytes also presented for cervical cancer, so a lot of really great abstracts are being presented.

References

1. Cheol Chung H, Delord JP, Perets R, et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. Presented at: Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer. March 22-25, 2021.

2. Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. Presented at: Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer. March 22-25, 2021.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content